Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · IEX Real-Time Price · USD
16.17
+0.14 (0.87%)
May 17, 2024, 4:00 PM EDT - Market closed
DAWN Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for DAWN stock have an average target of 38, with a low estimate of 33 and a high estimate of 44. The average target predicts an increase of 135.00% from the current stock price of 16.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DAWN stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +147.37% | May 7, 2024 |
| Needham | Needham | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +104.08% | May 7, 2024 |
| Needham | Needham | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +104.08% | Apr 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +209.21% | Apr 24, 2024 |
| Needham | Needham | Strong Buy Maintains $30 → $33 | Strong Buy | Maintains | $30 → $33 | +104.08% | Apr 24, 2024 |
Financial Forecast
Revenue This Year
13.33M
Revenue Next Year
75.80M
from 13.33M
Increased by 468.62%
EPS This Year
-2.67
from -2.37
EPS Next Year
-2.05
from -2.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.2M | 156.4M | 496.8M | 573.9M | 765.0M |
| Avg | 13.3M | 75.8M | 252.8M | 394.8M | 599.4M |
| Low | 3.3M | 14.8M | 117.2M | 254.8M | 408.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,072.8% | 555.4% | 127.1% | 93.8% |
| Avg | - | 468.6% | 233.5% | 56.2% | 51.8% |
| Low | - | 11.0% | 54.6% | 0.8% | 3.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.38 | -1.27 | 0.21 | 2.25 | 3.73 |
| Avg | -2.67 | -2.05 | -0.60 | 0.65 | 2.11 |
| Low | -2.83 | -2.72 | -1.50 | -0.25 | 0.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 471.0% |
| Avg | - | - | - | - | 223.8% |
| Low | - | - | - | - | 42.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.